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Abstract
Background: Mice deficient in apolipoprotein E (apoE
2/2) develop atherosclerosis. The possible linkage between
expression of adhesion molecules/cofactors and atherosclerosis was probed at the level of mRNA and protein expression.
The hypothesis of a linkage between changes of adhesion molecules/cofactors and atherosclerosis was tested further by
suppression of aortic lesion formation in apoE
2/2 mice by expression of very low levels of transgenic apolipoprotein E.
Methodology/Principal Findings: We show that at 8.5 months of age, the apoE
2/2 mice display elevated expression of
mRNA for LFA-1, MAC-1, VCAM-1, ICAM-1, and for CD44, as well as MCP-1, cathepsin B, and COX-2 (but not that for eNOS) in
atherosclerotic aortic arches. At earlier age, (10–13 week old) apoE
2/2 mice already display elevated expression of mRNA of
CD44, LFA-1, MAC-1, VCAM-1, ICAM-1, cathepsin, and of COX-2 in lesioned aortic arches. Expressing very low levels of
transgenic apolipoprotein E suppresses both aortic lesions and the expression of mRNA of LFA-1, VCAM-1, MCP-1, cathepsin
B, and of ICAM-1 in ApoE
2/2 mice. We tested at the level of protein, the observations obtained for mRNA expression. CD11a
(a component of LFA-1), VCAM-1 and cathepsin B expression was found to be elevated in apoE
2/2 aortas at 8–9 months;
low level expression of transgenic apolipoprotein E rectifies these changes.
Conclusions/Significance: Atherosclerotic lesions in apoE
2/2 mice are detected as early as 4 weeks of age. Expression of
low levels of apoE is shown to be both atheroprotective and to suppress these changes in key adhesion and inflammatory
molecules observed in early atherosclerotic lesions.
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Introduction
Atherosclerosis is a major contributor to the development of
cardiovascular disease, a leading cause of morbidity and mortality in
developed countries. Risk factors such as hypertension and
hyperlipidemia account for ,50% of the genetic risk for coronary
heart disease [1]. Therapeutics more effectively targeted to key
events in atherosclerosis are required to reduce its risk. Details of the
underlying molecular basis for atherosclerosis remain obscure. Some
important leads have been revealed through studies of knockout
mice.Developmentofatherosclerosis(induced bya varietyofmeans)
has been shown to be attenuated in mice made deficient in adhesion
molecules like P- and E-selectins or deficient in the chemokine
receptor CCR2 [2–5]. These studies reinforce the notion that
developing atherosclerosis involves an inflammatory response.
Mice-deficient in apolipoprotein E (apoE
2/2) spontaneously
develop pronounced aortic lesions characteristic of atherosclerosis
[6–8]. Earlier studies of expression of genes in apoE
2/2 mice on a
fat-enriched ‘‘Western’’ diet [9–11] or stimulated with lipopoly-
sachharide [12] focus essentially on analysis of atherosclerotic
lesion formation at late stages. One of the earliest steps in lesion
formation is the recruitment of monocyte/macrophages to the
subendothelial space of the vessel wall. Our overarching goal was
to investigate changes in key adhesion [e.g., VCAM-1, ICAM-1,
leukocyte ICAM-1 ligands CD11a/CD18 (LFA-1) and CD11b/
CD18 (Mac-1) [13], and adhesion protein CD44 [14]] as well as
chemokine [e.g., MCP-1 [15]] molecules/cofactors [3] involved in
monocyte adhesion during the initiation / early development of
atherosclerotic lesions. Expression of macrophage-derived protein
cathepsin B, the proatherogenic and antiatherogenic agent COX-
2 [16], and the regulator of vascular tone eNOS, also would be of
interest in analysis of developing atherosclerotic lesions. In the
current work, gene expression of key inflammatory and macro-
phage molecules is investigated in apoE
2/2 mice during the
initiation and progression of early atherosclerosis, as well as in
response to transgene expression of very low levels of apoE
(,2 mg/ml) which are remarkably atheroprotective in apoE
2/2
mice [17].
Results
mRNA expression of adhesion and inflammatory
molecules in aortic arches of older apoE
2/2 mice
Mice made deficient in apoE (apoE
2/2, KO) were maintained
on a standard chow diet. In the absence of a fat-enriched diet or
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2/2 display aortic arches rich in atheroscle-
rotic lesions at 11- , 8.5- or 5- months of age, as made visible by
staining of neutral lipids with Sudan IV stain (fig. 1). As others and
we have previously observed, there is a fairly wide variation in the
amount of atherosclerosis detected in apoE
2/2 mice. There is very
little variation in the transgenic mice, as there is almost total
suppression of lesion formation [17]. Control mice displayed no
such aortic lesions at either 8.5-months (fig. 1), 11- or 5-months of
age (not shown). We first probed gene expression in the apoE
2/2
mice that were 8.5 months of age, to optimize the detection of
possible changes in mRNA levels of targeted gene products in the
apoE
2/2 mice. To accomplish this goal, aortic arches were pooled
from either 8.5-months old apoE
2/2 or from control wild type
mice; mRNA was analyzed by real time PCR amplification. At
8.5-months of age, mRNA levels of adhesion molecules CD44 and
VCAM-1, their ligands LFA-1and MAC-1, and the chemoattrac-
tant MCP-1 were elevated by apoE deficiency (KO) as compared
to mRNA levels of aortic arches obtained from wild type (WT)
mice (fig. 2A). The increases ranged from 22.5-fold (VCAM-1),
9.1-fold (LFA-1), 6.0-fold (MCP-1), 2.8-fold (COX-2) to 2.5-fold
(CD44), with lesser increases in cathepsin-B and Cox-2, and no
change from WT for mRNA levels of eNOS (fig. 2A).
For apoE
2/2 mice engineered with a transgene to express very
low (,2 mg/ml) circulating levels of adrenal apoE (TG) that are
atheroprotective, atherosclerotic lesion formation is essentially
absent at 8.5 months (fig. 1). We next compared mRNA
expression of key adhesion molecules in aortic arches prepared
from these mice with those from apoE
2/2 mice (fig. 2A). The
mRNA values for the adhesion molecules/cofactors that were
elevated in the apoE
2/2 mice were reduced in their transgenic
counterparts that express very low levels of adrenal apoE. mRNA
levels for CD44 declined from 2.5- to 1.9-fold, for VCAM-1 from
22.5- to 16.0-fold, for LFA-1 from 9.1- to 4.8-fold, and for MCP-1
from 6.0- to 2.8-fold (fig. 2A). Expression of low levels of apoE
suppresses the expression of mRNA of these key adhesion
molecules in aortic arches and was atheroprotective. This
suppression occurred even against a background of high plasma
cholesterol (transgenic: 434.7655.1 mg/dl, knockout:
380.5670.6 mg/dl, p=0.55) which is equivalent between the
two groups. Protection from formation of atherosclerotic lesions in
apoE
2/2 mice by very low levels of apoE occurs, although the
suppression of the mRNA expression of the key molecules did not
reach wild type levels. Cathepsin-B gene expression in apoE
2/2
KO mice, for example, was higher than in wild-type mice (,1.5
fold). Expression of the apoE transgene, however, yields only a
modest decline in cathepsin-B mRNA when compared to that of
the WT mice. ICAM-1 and eNOS gene expression was found to
display only minor differences among all three groups (KO, TG,
and WT, fig. 2A).
mRNA expression in aortic arches of 13-weeks old mice
A primary goal of this work was to extend the analysis of mRNA
to mice in earlier stages of lesion formation, recognizing that the
amounts of starting tissue become a technical challenge. To this
end, we refined methods to measure mRNAs in aortic arches
surgically removed from individual mice, rather than in prepara-
tions from pooled aortic arches (fig. 2A). We exploited the
technology and pressed the analysis of lesion formation in
progressively younger mice (fig. 2B). At 13 weeks of age, apoE
2/
2 mice displayed substantially elevated levels of mRNA for
adhesion proteins CD44 (2.5-fold), ICAM-1 (1.7-fold), the
adhesion ligand LFA-1 (2.9-fold), and MAC-1 (3.0-fold) in their
aortic arches. Each of the other adhesion molecules/cofactors
displayed mRNA levels in apoE
2/2 mice that were only slightly
higher or equivalent to those prepared from aortic arches of the
WT mice.
The expression by transgene (TG) of very low levels of adrenal-
derived apoE in the 13-week old apoE
2/2 mice again resulted in
sharp reductions in the elevated mRNA levels of LFA-1, MAC-1,
ICAM-1 MCP-1, VCAM-1 and Cox-2 (fig. 2B). Of interest,
mRNA levels for VCAM-1, MCP-1, and Cox-2 in aortic arches of
apoE
2/2 mice were suppressed by transgenic expression of very
low apoE, reaching levels well below those observed in WT mice
(fig. 2B). Expression of CD44 mRNA and cathespsin-B mRNA, in
contrast, was largely unaffected by the transgenic expression of low
levels of apoE in the apoE
2/2 mice. mRNA levels of eNOS in the
apoE
2/2 mice harboring the transgene (TG) were higher than
either apoE
2/2 (KO) mice (p,0.01) or WT mice (p,0.05). Again,
Figure 1. Aortic arch lesion development in older apoE-deficient (apoE
2/2) mice. Mice were maintained on a chow diet. At 11-, 8.5- and 5-
months of age: effects of expression of very low levels of apoE on atherosclerotic lesion development. Aortas were stained with Sudan IV to show
neutral lipid deposits.
doi:10.1371/journal.pone.0002503.g001
ApoE Blocks Gene Expression
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of elevated plasma cholesterol (transgenic: 352.8641.7 mg/dl,
knockout: 266.4646.9 mg/dl, p=0.29) as compared to the wild
type, 119.0 mg/dl627.6.
Expression of mRNAs for these key molecules also was
examined in peripheral blood leukocytes. mRNA levels of the
adhesion molecules/cofactors were investigated in peripheral
leukocyte preparations to ascertain if mRNA levels in these
circulating cells would mirror those observed in the aortic arches.
Unlike the aortic arch preparations, the mRNA levels for these
molecules largely did not differ among the WT, KO, and TG
genotypes in preparations obtained from peripheral blood
leukocytes. Only the mRNA levels of MCP-1 were found to be
significantly elevated in peripheral blood leukocytes from the 13-
week old apoE
2/2 mice (fig. 3). This elevated MCP-1 mRNA level
remained elevated in the leukocytes of apoE
2/2 mice harboring
the transgene (fig. 3).
mRNA expression in aortic arches of 10-weeks old mice
We investigated the presence of atherosclerotic lesions in
younger apoE
2/2 mice in an effort to probe changes in the
mRNA of key molecules in lesions of involved aortic arches (fig. 4).
Lesion formation was obvious in arches of the 10-weeks old
apoE
2/2 mice (fig. 4). The presence of the adrenal apoE
transgene again effectively suppresses the formation of the lesions
in aortic arches of 10-week old (fig. 4) and younger (data not
shown) apoE
2/2 mice. We analyzed the mRNA expression in
these preparations cognizant that the ratio of lesion to non-
lesioned tissue in the arches was declining in younger animals and
‘‘diluting out’’ any changes that may exist. Using individual aortic
arches of 10-week old apoE
2/2 mice we were still able to detect
increased expression of mRNA of CD44, LFA-1, VCAM-1,
ICAM-1, COX-2, and cathepsin B in comparison to mRNA
expression in aortic arches of the WT mice (fig. 5A). As observed
in the 8.5-month and 13-week apoE
2/2 mice, the enhanced
expression of LFA-1, ICAM-1, and VCAM-1 mRNA were
sensitive to the expression of the very low levels of adrenal apoE
produced in the apoE
2/2 mice harboring the transgene (fig. 5A).
Cathepsin-B mRNA expression also was significantly suppressed
in aortic arches of 10-week old apoE
2/2 mice harboring the
transgene. mRNA levels of MCP-1 and eNOS in aortic arch
preparations among the three 10-week-old groups (KO, TG, WT),
in contrast, did not vary significantly. As for the previous age
groups, there is no difference between the plasma cholesterol levels
in the two knockout groups, which are both elevated (transgenic:
304.9682.6, knockout: 307.9670.0, p=0.98).
mRNA expression in aortic arches of 6-weeks old mice
Atherosclerotic lesions were detected at 6-weeks and even at 4-
weeks of age in the apoE
2/2 mice (fig. 4). We probed the mRNA
levels for these same molecules, key to inflammation and
macrophage activation, in aortic preparations prepared from mice
at 6 weeks of age (fig. 5B). Severely limited by the amount of
starting tissue, the analysis of mRNA in aortic arches of 6-week-old
mice required that we pool aortic arches from at least 6 animals to
obtain reliable measurements. The mean levels of mRNA for
Figure 2. Gene expression of CD44, LFA-1, MAC-1, VCAM-1,
MCP-1, cathepsin B, eNOS, ICAM-1, and COX-2 in of older mice.
A, gene expression in pooled aortic arches expressed as % change
relative to wild type (KO: n=10; TG: n=10; WT: n=5) from 8.5 mo old
mice on chow diet, all normalized to cyclophilin D mRNA levels. TG is
apoE
2/2 expressing low-level transgenic apoE, KO is apoE knockout,
and WT is wild type. B, mRNA expression of adhesion molecules/
cofactors in individual aortic arches (KO: n=13; TG: n=19, WT: n=10)
from 13 week old mice on a chow diet, normalized to cyclophilin D
mRNA levels. CD44, LFA-1 and MAC-1 RNA levels were elevated in
apoE
2/2 mice compared to wild type mice (Bonferroni test, *p,0.05,
**p,0.01, ***p,0.0001). Low-level apoE suppressed LFA-1, VCAM-1,
MCP-1 and COX-2 gene expression in transgenic mice compared to
apoE
2/2 mice (Bonferroni test, {p,0.05, {p,0.01).
doi:10.1371/journal.pone.0002503.g002
Figure 3. CD44, LFA-1, MAC-1, VCAM-1, MCP-1 and cathepsin B
mRNA levels in 13 week old mouse blood leukocytes. Gene
expression in blood leukocytes from 13 week old mice on a chow diet,
all normalized to cyclophilin D and expressed as % change relative to
wild type (KO: n=22; TG: n=12; WT: n=11). TG is apoE
2/2 expressing
low-level transgenic apoE, KO is apoE knockout, and WT is wild type.
Leukocytes were prepared as described in Materials and Methods. The
gene expression levels were not different between the groups for all
the genes tested except for MCP1, which was significantly elevated in
the KO and TG groups (Bonferroni test, *p,0.0001) relative to wild type.
doi:10.1371/journal.pone.0002503.g003
ApoE Blocks Gene Expression
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weeks old apoE
2/2 mice (fig. 5B). The trend of the transgene
expression of very low levels of apoE suppressing VCAM-1,
ICAM-1 and Cox-2 mRNA expression observed in the 8.5-
months old and 10–13 weeks old apoE
2/2 mice appears to extend
to the pooled aortic preparations from the 6-weeks old mice,
although the changes were less marked. The technical difficulties
encountered with analysis of small lesions on very small aortic
aches of 6-weeks old mice precluded analysis at the mRNA level of
tissue from aortic arches of 4-weeks old apoE
2/2 mice, although
the arches do display some very early atherosclerotic lesions (fig. 4).
Expression of adhesion and inflammatory molecules at
the protein level in lesioned and atheroprotected aortas
of apoE
2/2 mice
We investigated the changes observed in mRNA for VCAM-1
and cathepsin B at the protein level in aortas from 8–9 month-old
mice. The expression of wild type (WT), apoE
2/2 (KO), and
apoE
2/2 mice+transgenic mice (TG, fig. 6), as determined by
immunoblotting of samples (0.1 mg protein) of aorta lysates
subjected to SDS-PAGE and electrophoretic transfer of resolved
proteins to blots. There was a trend toward increased expression of
VCAM-1 and cathepsin-B in aorta lysates of the apoE
2/2 mice. A
wide variation in the level of lesion burden in apoE
2/2 mice
complicates an immunoblot analysis. At the same age, apoE
2/2
mice can display extensive lesion development or little [17].
Expression of the very low levels of apoE from the adrenal,
reversed the increase in expression provoked in the apoE
2/2 mice.
The presence of the transgene is sufficient to suppress the protein
expression of VCAM-1 relative to WT and apoE
2/2 (p,0.05,
n=6). Actin levels were measured in the immunoblots to verify
equivalent protein loading.
In situ staining of LFA-1 and VCAM-1expression in WT,
KO, and KO+TG mice
Our mRNA analysis enabled us to detect elevated expression of
key molecules in the aortas of mice with atherosclerotic lesions
(apoE
2/2), advancing from detection in 8.5 months to 6–10 weeks
of age. Further, our ability to make use of the adrenal transgene to
express very low levels of apoE sufficient to suppression lesion
formation in apoE
2/2 mice was key in testing linkages between
Figure 4. Aortic arch lesion development in apoE
2/2 : effects of
expression of very low levels of apoE. Aortas were stained with
Sudan IV to show deposits of neutral lipid. Atherosclerotic lesions
appeared in the aortic arch of apoE
2/2 as early as 4 weeks old. More
lesions were observed as the mice aged. For apoE
2/2 mice expressing
very low levels of apoE, no aortic arch lesions were detected. The arrows
point to lesions.
doi:10.1371/journal.pone.0002503.g004
Figure 5. Gene expression of CD44, LFA-1, MAC-1, VCAM-1,
MCP-1, cathepsin B, eNOS, ICAM-1, and COX-2 in younger
mice. Gene expression of CD44, LFA-1, MAC-1, VCAM-1, MCP-1,
cathepsin B, eNOS, ICAM-1, and COX-2 in individual aortic arches
expressed as % change relative to wild-type (n=8 for all groups) from
10- (A) week old mice. Data from 6- (B) week old mice are from pooled
aortas, due to the small sample size. Both sets of mice were on chow
diet and normalized to cyclophilin D mRNA levels. ApoE
2/2 mice had
higher CD44, LFA-1, VCAM-1, cathepsin B, ICAM-1 and COX-2 gene
expression than wild type mice (Bonferroni test, *p,0.05, **p,0.01,
***p,0.0001). Low-level apoE in transgenic mice suppressed the gene
expression of LFA-1, VCAM-1, cathepsin B and ICAM-1 compared to
apoE
2/2 mice (Bonferroni test, {p,0.05, {p,0.0001).
doi:10.1371/journal.pone.0002503.g005
ApoE Blocks Gene Expression
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over expression of cathepsin-B and VCAM-1 in apoE
2/2 mice,
analysis by immunoblotting was able to confirm the results
obtained at the level of message. To advance the analysis further,
we probed in situ immunohistochemically aortic root areas from 8–
9 month mice from the WT, KO, and KO+TG groups (fig. 7). Oil
red O staining was employed to locate forming lesions (i.e., regions
of lipid deposition). Adjacent sections of these aortic preparations
were then stained for VCAM-1 and LFA-1 (the CD11a
component of LFA-1). Unlike VCAM-1 antibodies, antibodies
available against CD11a were found to be of little use in
immunoblotting assays.
Oil red O staining for neutral lipids was absent in the aortic root
areas of WT mice, extensive in the apoE
2/2 KO mice, and much
less detectable in the KO+TG mice (left-handed panel, fig. 7).
Areas of oil red O staining enclosed by the boxes are magnified in
the center (CD11a staining) and right-handed (VCAM-1 staining)
panels. The adhesion marker staining closely followed the lipid
staining in the lesion areas, with little to none seen in the WT
aortic root, even in the lesion-prone shoulder areas of the valves.
In the equivalent area of the apoE
2/2 aorta there was abundant
staining for both CD11a (center panel) and VCAM-1 in cells that
appear to be lipid loaded macrophages (left-handed panel, fig. 7).
In the aortic roots of the KO+TG mice there was only a small
amount of staining for both adhesion molecules. This limited
staining in the KO+TG mice tissue was localized to an area with
some residual lipid deposition. The amount of staining of adhesion
molecules in apoE
2/2 mice harboring the apoE adrenal transgene
was considerably less than that observed in the apoE
2/2 mice
(fig. 7).
Discussion
Recruitment of circulating monocytes to the arterial intima is an
early event in formation of atherosclerotic lesions [18]. Adhesion
molecules and cofactors such as cytokines, which can tether and
activate integrin complexes, initiate the movement of monocytes
and T-lymphocytes from the circulation into the vessel wall [19].
Changes in the expression of adhesion molecules and their
cofactors might be critical to initiation and/or progression of
atherosclerotic lesions. We tested this hypothesis directly through
analysis of key adhesion and inflammatory molecules in athero-
sclerotic lesions of aortic arches of apoE
2/2 mice. The leukocyte
ligands LFA-1 and MAC-1 for the adhesion molecule ICAM-1
have been implicated in lesion formation [11,20]. Increased
expression of LFA-1 and MAC-1 mRNAs was observed in
lesioned aortic arches of apoE
2/2 mice at 8.5 months as well as
13-weeks of age. Up-regulation of LFA-1 mRNA in aortic arches
of apoE
2/2 mice was detected as early as 10 weeks (2-fold),
progressing in 13-weeks (2.9-fold), and 8.5-months (9.1-fold) old
KO mice. mRNA levels for MAC-1 increased in the aortic arches
of apoE
2/2 mice, increasing 3.0-fold at 13-weeks of age and
remaining at 3.3-fold at 8.5-months of age. Up-regulation of
ICAM-1 adhesion molecule was detected in apoE
2/2 mice, as
early as 10- and 13-weeks of age. By 8.5 months of age, ICAM
mRNA returned to normal levels, suggesting that ICAM, LFA-1,
and MAC-1 may play more important roles in the initiation and/
or early progression of atherosclerotic lesions.
VCAM-1 is an immunoglobulin-like adhesion molecule ex-
pressed on activated endothelial cells. VCAM-1 promotes
monocyte adhesion and accumulation on the vessel wall at
lesion-prone sites [21]. VCAM-1 mRNA levels increased by more
than 20-fold at 8.5-months of age. Increased expression of
adhesion molecule VCAM-1 mRNA was observed in aortic
arches of apoE
2/2 mice as early as 10- and 13- weeks of age.
Immunoblotting data and immunohistochemical analysis of
VCAM-1 expression support a role of this adhesion molecule in
formation of atherosclerotic lesions. Deficiency of VCAM-1 has
been shown to diminish the formation of early foam cell lesions
throughout the aorta of low-density lipoprotein receptor-deficient
(LDLR
2/2) mice, promoting VCAM-1 as a major role in the
Figure 6. Protein Levels of VCAM-1 and cathepsin B in aortas.
Total aorta protein from apoE
2/2 chow-fed mice at 8–9 months of age
(100 mg protein/lane) was resolved by 10% denaturing SDS-PAGE and
Western blots conducted as described in the Materials and Methods. Six
separate aorta lysates were run each for wild type (WT), apoE
2/2 (KO),
or apoE
2/2 expressing low-level transgenic apoE (TG ). The image
bands were scanned and analyzed using Image Quant software. Actin
was immunostained as a loading control (Mann Whitney test, *p,0.03).
doi:10.1371/journal.pone.0002503.g006
Figure 7. Immunohistochemistry of aortic root lesions. Aortas
from 8–9 month chow fed male mice were fixed and sectioned as
described in Materials and Methods. Sections were stained for neutral
lipid accumulation with oil red O, then adjacent sections were
immunostained for VCAM-1 and CD11a (LFA-1) as described. Wild type
(WT), apoE
2/2 (KO), and apoE
2/2 expressing low level transgenic apoE
(TG) are indicated for each row. Representative photomicrographs are
shown, with the magnifications at the bottom of each column. The
areas in the boxes in the oil red O column are magnified in the VCAM-1
and CD 11a columns.
doi:10.1371/journal.pone.0002503.g007
ApoE Blocks Gene Expression
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suppression of lesion formation in apoE
2/2 mice with very low
levels of apoE, levels not capable of rectifying the elevated lipids
observed in apoE
2/2 mice, were accompanied by a sharp decline
in VCAM-1 mRNA and protein expression.
The chemoattractant cytokine MCP-1 is well known to
stimulate macrophage recruitment in atherosclerosis, and so it
was a high value target for our studies. MCP-1 gene expression, as
measured by mRNA levels, in aorta was increased by 6.0 fold in
apoE
2/2 mice at 8.5-months of age. Furthermore, expression of
MCP-1 mRNA was found to be elevated even earlier, at 10- and
13-weeks of age in apoE
2/2 mice. Since levels of expression of
MCP-1 mRNA appeared to increase with the age of the apoE
2/2
mice, MCP-1 may be playing a more important role in the later
rather than early stages of atherosclerosis. Expression of low levels
of apoE from the transgene suppressed aortic lesions and
attenuated the increase in MCP-1 in apoE
2/2 mice. In mice
lacking either MCP-1 [15] or its receptor, CCR2 [3] atheroscle-
rosis is depressed. The pattern of changes of MCP-1 gene
expression was similar to that of the VCAM-1 gene. It should be
noted that both MCP-1 and VCAM-1 genes display NF-kB
consensus DNA-binding sites in the 59- flanking regions [23,24]. In
contrast, the circulating leukocyte levels of MCP-1 were elevated
in both the apoE
2/2 and transgenic mice, perhaps indicating
different roles for blood leukocyte and vessel wall expressed MCP-
1 in the low level apoE suppression of atherosclerosis.
The hyaluronan receptor CD44 plays a critical role in the
progression of atherosclerosis through multiple mechanisms,
including inflammatory cell recruitment and cellular activation
[14,23,25]. CD44 mRNA levels in aorta of the apoE
2/2 mice
were increased at 10-weeks of age (1.6-fold), at 13-weeks of age
(2.5-fold), maintaining elevated levels at 8.5 months of age (2.4-
fold). The expression of low levels of apoE, however, only had a
modest effect on CD44 mRNA levels in aortic arches of apoE
2/2
mice, suggesting a less obvious linkage of CD44 and the
atheroprotective effects of apoE.
Finally, cathepsins are macrophage lysosomal cysteine proteases
that can accelerate the degradation of extracellular matrix at sites
of inflammation, which may include cathepsin B [26]. Our results
showing increased expression of cathepsin B mRNA in the aorta of
apoE
2/2 mice, as early as 10 weeks of age, support this possible
role. Furthermore, elevated cathepsin B mRNA levels were
suppressed in the apoE
2/2 mice expressing atheroprotective
levels of apoE by transgene. Increased expression of cathepsin B
gene can be detected in apoE
2/2 mice following a 20-week diet
high in fat content [9]. Cathepsin B has the ability to degrade
native and modified low-density lipoprotein, which in turn can
provoke accumulation of modified LDL in the vessel wall and
promote foam cell formation [27]. In humans, atherosclerotic
aortas also show increased cathepsin activity [28].
The suppression of these messages occurred even with elevated
plasma cholesterol in both the apoE
2/2 and the low level apoE
mice. The total plasma cholesterols for both of these groups were
not significantly different at any age. We previously showed that
the lipoprotein particle distributions were identical between these
groups of mice by FPLC lipoprotein profile analysis, and the
highly sensitive technique of laser light scattering[17]. This makes
it unlikely that the effects we observed on vessel wall mRNAs is
due to apoE’s well-characterized role in lipoprotein clearance.
Previous work has shown that apoE blocks mitogen-stimulated T-
lymphocyte activation[29–31], an effect that might restrict
inflammatory responses in atherosclerotic lesions. In cell culture
studies, apoE was found to inhibit platelet aggregation[32],
to inhibit platelet-derived growth factor (PDGF)-stimulated
migration and proliferation of vascular smooth muscle cells[33] ,
and to suppress TNF a-stimulated VCAM-1 expression in
endothelial cells[34] actions that could be anti-atherogenic within
vascular lesions. Cell culture studies suggest that apoE disrupts
PDGF signaling in smooth muscle cells via interaction with
LRP[35,36] . We are currently studying the receptors and
signaling pathways that may be involved in mediating the actions
of low level apoE we observed in these mice.
Remarkably, atherosclerotic lesion formation was detectable as
early as 4-weeks of age in apoE
2/2 mice, an age at which details
about atherogenesis are few. By profiling of mRNA expression of
key molecules involved in inflammation and activation of
macrophages we succeeded in extending the characterization of
mRNA expression of many of these molecules in apoE
2/2 mice to
as early as 10-weeks of age. The availability of apoE
2/2 mice in
which low levels of apoE expression by an adrenal transgene is
atheroprotective enabled us to test the changes in mRNA with the
onset of the lesions as well as with the atheroprotective properties
of low-level apoE secretion. Relatively small, diffuse lesions in
aorta of 4- to 6-week old apoE
2/2 mice, made visible by oil red O
staining of lipid, now focus our attention on the initiation and early
development of the atherosclerotic lesions. In future work we will
employ techniques in which analysis of such small lesions will not
be ‘‘diluted’’ in biopsies by the presence of adjacent, largely
healthy aortic tissue.
Materials and Methods
Animals
Mice were maintained in a specific pathogen-free environment
on a 12 h light, 12 h dark cycle. Only males were recruited into
this study and the mice were on a chow diet containing 4.5% fat
(PicoLab Rodent Diet 20, LabDiet) and water ad libitum. Wild
type, apoE deficient (apoE
2/2) mice, and the 619 transgenic line,
which expresses too little apoE (,1% to 2% of wild type) to
correct their plasma cholesterol levels [17] were on a mixed 9:1
FVB/N6C57BL/6 genetic background. Transgenic mice and
apoE
2/2 mice used were siblings. Four groups of mice at different
ages were studied for RNA expression analysis: in the first group
(8.560.4 month), aortic arches of 10 apoE
2/2 mice, 10 apoE
2/2
with low transgenic apoE and five wild type mice were pooled. In
the second group (12.961.4 week), aortic arches (apoE
2/2: n=13,
apoE
2/2 with low transgene: n=19, wild type: n=10) were
collected individually. In the third group (10.160.2 week), eight
aortic arches of apoE
2/2, apoE
2/2 with transgene and wild type
mice were collected individually. In the fourth group (5.960.1
week), aortic arches of six each apoE
2/2, apoE
2/2 with transgene
and wild type mice were pooled. Mice were sacrificed by
exsanguination under Ketamine Hydrochloride (100 mg/ml,
Abbott Laboratories) and Xylazine (20 mg/ml, Phoenix Scientific
Inc.) (3:2) anesthesia. The Stony Brook University Committee on
Laboratory Animal Resources approved housing and experimen-
tal procedures.
RNA extraction
Aortas were perfused with RNAlater (Ambion) by heart puncture,
adventitia removed, and the arches stored in RNAlater at 280uC
priortoRNAextraction.Inthe younger groups,bloodwascollected
by heart puncture before perfusion and total RNA was extracted
from total circulatingwhite cells remaining after red cell lysis. Aortic
arches were homogenized in TRIZOL Reagent and total RNA was
extracted according to the manufacturer’s instructions (Invitrogen).
RNA concentration was measured using RiboGreen
TM RNA
Quantitation Reagent, (Molecular Probes). The RNA yield from
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4.2 mg for white cells. First strand cDNA was synthesized using 1
st
Strand cDNA Synthesis Kit (Roche Diagnostic).
Preparation of DNA standards
VCAM-1, ICAM-1, LFA-1, COX-2 and Cyclophilin D cDNA
cloning was performed using a PCR-Script
TM Amp cloning Kit
(Stratagene) with cDNA sequences obtained from GenBank.
MCP-1 (Image clone ID; 5351355), LFA-1 (Image clone ID:
4015574), MAC-1 (Image clone ID: 3810731) and Cathepsin B
(Image clone ID: 1887225) cDNA clones were purchased from
ATCC. eNOS and CD44 clones were kindly provided by Dr.
Philip A. Marsden’s laboratory at the University of Toronto and
Dr. Thomas P. St. John (ICOS Corporation) respectively. All
clones were confirmed by sequencing. Standard curves were built
using serial dilutions of cDNA (1/10 dilution, 1–10
26 ng).
Real-time PCR-Primers were designed for each gene using
Primer3 software (1997 Whitehead Institute for Biomedical
Research) or GeneRunner (version 3.00, 1994 Hastings Software,
Inc). Amplicons of 50–300 bp with Tm 57–63uC and G/C
content 30–80% were selected. Cyclophilin D was used as an
endogenous control. The sequences of primers and product
lengths are as follows: LFA-1, ATGCACCAAGTACAAAGT-
CAGC and TTGGTCGAACTCAGGATTAGC (202 bp); MAC-
1, CTGAACATCCCATGACCTTCC and GCCCAAGGACA-
TATTCACAGC (209 bp); Cathepsin B, TGACCAGTGCC-
CATGACAAGC and CATTGTTCCCGTGCATCAAAGG
(229 bp); CD44, TCCTTCGATGGACCGGTTACC and GT-
GGAGCCGCTGCTGACATC (137 bp); VCAM-1, TAC-
CAGCTCCCAAAATCCTG and TCTGCTAATTCCAGCCTCGT
(152 bp); ICAM-1, GTGATCCCTGGGCCTGGTG and GGAAAC-
GAATACACGGTGATGG (278 bp); MCP-1, CTGGATCGGAAC-
CAAATGAG and AAGGCATCACAGTCCGAGTC (203 bp); eNOS,
TGACCAGCACATTTGGCAATGG and CATGAGCGCTGCTG-
CAAAGC (65 bp); COX-2, GCCCAGCACTTCACCCATCAG and
AAGTCCACTCCATGGCCCAGTC (86 bp); Cyclophilin D,
TCCAAGAACCCGCGAGTCTTC and CCGGTCGTGGACC-
CAGTT (152 bp).
Real-time PCR was carried out in a 20 ml volume with 1 ml
reverse transcription reaction of plasmid DNA, 0.3 mM primer
and 10 ml2 6 QuantiTect SYBR Green PCR Master Mix
(QIAGEN). PCR reactions were run in the LightCycler system
(Roche Molecular Biochemicals) following manufacturer proto-
cols. Each sample was run in duplicate and mean values were used
for analysis. Sample concentration was determined from the
standard curve for each gene. Quantification of target gene
mRNA was expressed as the ratio of the target gene to cyclophilin
D. Melting curve analysis was performed to differentiate specific
product from non-specific PCR products or primer-dimers.
Determinations of atherosclerosis
Mice at different mean ages (11 month, 8.5 month, 5 month, 10
week, 6 week and 4 week) were sacrificed. Aortas were perfused
with PBS and dissected, then fixed in neutral buffered formalin for
48 hours at 4uC. Aortas were stained with Sudan IV, as previously
described [37]. The aortic tree was opened longitudinally and
lesion images were captured with a macro lens and digital camera.
Western Blots
Lysates were made from aortas (arch and thoracic segments)
from male chow-fed mice 8–9 months old, as described [17].
100 mg of total lysate protein per lane was resolved by 10%
denaturing SDS-PAGE. The resolved proteins were transferred
electrophoretically to a nitrocellulose membrane and immuno-
stained using a rabbit anti-actin antibody (SIGMA), affinity
purified goat anti-mouse VCAM-1, or cathepsin B (R&D
Systems). The secondary antibody was either a peroxidase-coupled
anti-goat IgG (R&D Systems) or peroxidase-coupled anti-rabbit
IgG (GE Healthcare Lifesciences). Bands were visualized by
enhanced chemiluminescence (Pierce). The blot was stripped
between each immunostaining using Restore
TM Western Blot
Stripping Buffer (Pierce). To quantitate the protein bands, films of
the blots were scanned and the images analyzed with Image Quant
5.2 (Molecular Devices).
Immunohistochemistry
Mice were perfused through the left ventricle with PBS followed
by 4% formaldehyde in PBS. Frozen sections through the aortic
root were stained with oil red O and lightly counterstained with
hematoxylin as previously described [38]. The primary antibodies
used for immunohistochemistry of adjacent frozen sections were
the anti-VCAM-1 above, and a rat anti-mouse CD11a monoclo-
nal antibody (eBioscience). A Vectastain ABC Elite kit (Vector
Laboratories) was used for detection, with DAB staining, and
hematoxylin counterstaining.
Statistical analysis
In the 8.5-months and 6-weeks old groups, more than two-fold
change in mRNA expression was considered significant enough to
warrant further investigation. For the 13- and 10-weeks old
groups, Statistics Package for the Social Sciences (SPSS version
10.0.1, 1999, SPSS Inc, Chicago, IL) was employed for data
analysis. Analysis of variance was performed comparing the
mRNA expression levels among the groups with Bonferroni post
hoc tests. Non-parametric tests were employed to analyze the
unevenly distributed data. The protein data were analyzed using
unpaired t-tests. Values were expressed as mean6S.E.M., unless
otherwise indicated. A value of p,0.05 was considered significant.
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